DK1599453T3 - 3-Methyl-2-(3-(2-phenyloxazol-4-ylmethyoxy)cyclohexancarbonylamino)smörsyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerose - Google Patents

3-Methyl-2-(3-(2-phenyloxazol-4-ylmethyoxy)cyclohexancarbonylamino)smörsyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerose

Info

Publication number
DK1599453T3
DK1599453T3 DK04712494T DK04712494T DK1599453T3 DK 1599453 T3 DK1599453 T3 DK 1599453T3 DK 04712494 T DK04712494 T DK 04712494T DK 04712494 T DK04712494 T DK 04712494T DK 1599453 T3 DK1599453 T3 DK 1599453T3
Authority
DK
Denmark
Prior art keywords
cyclohexanecarbonylamino
phenyloxazol
ylmethoxy
atherosclerosis
diabetes
Prior art date
Application number
DK04712494T
Other languages
Danish (da)
English (en)
Inventor
Christian Stapper
Dirk Gretzke
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Heiner Glombik
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1599453T3 publication Critical patent/DK1599453T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK04712494T 2003-02-27 2004-02-19 3-Methyl-2-(3-(2-phenyloxazol-4-ylmethyoxy)cyclohexancarbonylamino)smörsyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerose DK1599453T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001578 WO2004076426A1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
DK1599453T3 true DK1599453T3 (da) 2009-08-24

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
DK04712490T DK1599452T3 (da) 2003-02-27 2004-02-19 3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw
DK04712494T DK1599453T3 (da) 2003-02-27 2004-02-19 3-Methyl-2-(3-(2-phenyloxazol-4-ylmethyoxy)cyclohexancarbonylamino)smörsyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerose
DK04712503T DK1599455T3 (da) 2003-02-27 2004-02-19 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04712490T DK1599452T3 (da) 2003-02-27 2004-02-19 3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04712503T DK1599455T3 (da) 2003-02-27 2004-02-19 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose

Country Status (34)

Country Link
US (5) US7259177B2 (US07259177-20070821-C00075.png)
EP (3) EP1599455B1 (US07259177-20070821-C00075.png)
JP (3) JP2006519193A (US07259177-20070821-C00075.png)
KR (3) KR20050106462A (US07259177-20070821-C00075.png)
CN (3) CN100439345C (US07259177-20070821-C00075.png)
AR (3) AR043427A1 (US07259177-20070821-C00075.png)
AT (3) ATE430738T1 (US07259177-20070821-C00075.png)
AU (3) AU2004215672B2 (US07259177-20070821-C00075.png)
BR (3) BRPI0407814A (US07259177-20070821-C00075.png)
CA (3) CA2517386A1 (US07259177-20070821-C00075.png)
CL (2) CL2004000392A1 (US07259177-20070821-C00075.png)
CO (2) CO5690580A2 (US07259177-20070821-C00075.png)
DE (4) DE10308355A1 (US07259177-20070821-C00075.png)
DK (3) DK1599452T3 (US07259177-20070821-C00075.png)
EC (2) ECSP055985A (US07259177-20070821-C00075.png)
ES (3) ES2326418T3 (US07259177-20070821-C00075.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00075.png)
IL (2) IL170314A (US07259177-20070821-C00075.png)
MA (3) MA27737A1 (US07259177-20070821-C00075.png)
MX (3) MXPA05008988A (US07259177-20070821-C00075.png)
NO (3) NO20054396L (US07259177-20070821-C00075.png)
OA (2) OA13035A (US07259177-20070821-C00075.png)
PA (1) PA8596801A1 (US07259177-20070821-C00075.png)
PE (3) PE20050292A1 (US07259177-20070821-C00075.png)
PL (3) PL378437A1 (US07259177-20070821-C00075.png)
PT (3) PT1599453E (US07259177-20070821-C00075.png)
RS (1) RS20050594A (US07259177-20070821-C00075.png)
RU (3) RU2005129992A (US07259177-20070821-C00075.png)
SA (1) SA04250153A (US07259177-20070821-C00075.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00075.png)
TW (3) TW200500349A (US07259177-20070821-C00075.png)
UY (2) UY28210A1 (US07259177-20070821-C00075.png)
WO (3) WO2004076427A1 (US07259177-20070821-C00075.png)
ZA (2) ZA200505768B (US07259177-20070821-C00075.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP2052728B1 (en) 2006-08-10 2018-06-13 mimozax Co., Ltd. Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia
US8481778B2 (en) 2007-08-16 2013-07-09 Solvay (Societe Anonyme) Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
CN101959875B (zh) 2008-02-29 2013-10-16 日产化学工业株式会社 噻吩化合物及其中间体的制造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
RU2745019C1 (ru) 2017-12-13 2021-03-18 Кэнон Кабусики Кайся Картридж и устройство формирования изображений
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
HUP0003999A3 (en) 1997-07-16 2003-03-28 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
AU782404B2 (en) * 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
JP4598278B2 (ja) 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ppar受容体リガンドとしてのジアリール酸誘導体
US6284766B1 (en) 1999-04-30 2001-09-04 Neurogen Corporation 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
WO2000078312A1 (en) 1999-06-18 2000-12-28 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ, インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
PT1204654E (pt) 1999-07-29 2003-11-28 Lilly Co Eli Benzofurilpiperazinas agonistas do receptor 5-ht2c da serotonina
AU774071B2 (en) 1999-09-01 2004-06-17 Sanofi-Aventis Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
TR200401333T4 (tr) 1999-12-03 2004-08-23 Astrazeneca Ab (S)-2 Etoksi -3-4- (2-4-Metansulfoniloksifenil Etoksi) Fenil] Propanoik Asidin Kristal Formu
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
JP2003528135A (ja) 2000-03-31 2003-09-24 プロバイオドラッグ アーゲー 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
YU80302A (sh) 2000-04-25 2005-11-28 Kyorin Pharmaceutical Co. Ltd. Novi stabilni kristal derivata tiazolidinediona i postupak za proizvodnju istog
CA2407538C (en) 2000-04-28 2007-01-09 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
WO2001094300A1 (de) 2000-06-09 2001-12-13 Aventis Pharma Deutschland Gmbh Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
CN1471517A (zh) * 2000-08-23 2004-01-28 Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
DE50111751D1 (de) 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EP1726586A1 (en) * 2000-12-25 2006-11-29 Ono Pharmaceutical Co., Ltd. Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
CA2438551A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
MXPA03010903A (es) * 2001-06-07 2004-02-17 Lilly Co Eli Moduladores de receptores activados por el proliferador de peroxisomas.
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
NZ531440A (en) 2001-08-31 2005-10-28 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
AU2003207432A1 (en) 2002-02-05 2003-09-02 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
RS20050594A (en) 2007-12-31
ATE430738T1 (de) 2009-05-15
JP2006519194A (ja) 2006-08-24
AU2004215673B2 (en) 2009-10-01
AU2004215673A1 (en) 2004-09-10
PT1599455E (pt) 2009-09-29
KR20050106461A (ko) 2005-11-09
DK1599455T3 (da) 2009-11-09
CN100398526C (zh) 2008-07-02
AR043432A1 (es) 2005-07-27
CA2516620A1 (en) 2004-09-10
DE10308355A1 (de) 2004-12-23
DE502004009690D1 (de) 2009-08-13
US20080015238A1 (en) 2008-01-17
ES2326418T3 (es) 2009-10-09
PE20040959A1 (es) 2005-01-17
BRPI0407758A (pt) 2006-02-14
DE502004004139D1 (de) 2007-08-02
US7365084B2 (en) 2008-04-29
CO5690578A2 (es) 2006-10-31
AU2004215677A1 (en) 2004-09-10
ES2287700T3 (es) 2007-12-16
UY28209A1 (es) 2004-09-30
TNSN05204A1 (en) 2007-06-11
AR043433A1 (es) 2005-07-27
BRPI0407814A (pt) 2006-02-14
BRPI0407907A (pt) 2006-02-14
US20040209920A1 (en) 2004-10-21
MA27737A1 (fr) 2006-02-01
DE502004009453D1 (de) 2009-06-18
DK1599452T3 (da) 2007-10-01
OA13034A (en) 2006-11-10
AU2004215672A1 (en) 2004-09-10
CL2004000391A1 (es) 2005-01-07
ECSP055985A (es) 2006-01-16
AU2004215672B2 (en) 2010-01-07
TNSN05206A1 (en) 2007-06-11
PL377735A1 (pl) 2006-02-20
PT1599453E (pt) 2009-07-14
US7335671B2 (en) 2008-02-26
CA2517381A1 (en) 2004-09-10
CN1753879A (zh) 2006-03-29
MXPA05008951A (es) 2005-11-04
MA27736A1 (fr) 2006-02-01
TW200510352A (en) 2005-03-16
ES2329366T3 (es) 2009-11-25
NO20054396L (no) 2005-11-11
EP1599452B1 (de) 2007-06-20
KR20050106462A (ko) 2005-11-09
US20050215596A1 (en) 2005-09-29
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
JP2006519193A (ja) 2006-08-24
EP1599455A1 (de) 2005-11-30
ZA200505768B (en) 2005-11-23
UY28210A1 (es) 2004-09-30
EP1599452A1 (de) 2005-11-30
WO2004076427A1 (de) 2004-09-10
PE20050292A1 (es) 2005-05-24
NO20054408D0 (no) 2005-09-22
RU2005129992A (ru) 2006-02-10
RU2005129995A (ru) 2006-01-27
NO20054398L (no) 2005-11-02
CN100439347C (zh) 2008-12-03
CN100439345C (zh) 2008-12-03
OA13035A (en) 2006-11-10
ZA200505765B (en) 2006-05-31
ATE365159T1 (de) 2007-07-15
HRP20050744A2 (en) 2006-09-30
RU2005130002A (ru) 2006-01-27
EP1599455B1 (de) 2009-07-01
NO20054396D0 (no) 2005-09-22
EP1599453A1 (de) 2005-11-30
KR20050105492A (ko) 2005-11-04
TW200500349A (en) 2005-01-01
PE20050293A1 (es) 2005-05-24
AU2004215677B2 (en) 2010-01-07
US7872034B2 (en) 2011-01-18
ECSP055986A (es) 2006-01-16
MA27742A1 (fr) 2006-02-01
CN1756748A (zh) 2006-04-05
CO5690580A2 (es) 2006-10-31
AR043427A1 (es) 2005-07-27
PL378130A1 (pl) 2006-03-06
US7259177B2 (en) 2007-08-21
PT1599452E (pt) 2007-09-12
US20050101637A1 (en) 2005-05-12
MXPA05008995A (es) 2005-10-18
JP2006519199A (ja) 2006-08-24
PL378437A1 (pl) 2006-04-03
EP1599453B1 (de) 2009-05-06
US20080167354A1 (en) 2008-07-10
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
TW200508210A (en) 2005-03-01
HRP20050742A2 (en) 2006-09-30
IL170314A (en) 2010-11-30
ATE435217T1 (de) 2009-07-15
CN1753881A (zh) 2006-03-29
NO20054398D0 (no) 2005-09-22
MXPA05008988A (es) 2005-10-18
WO2004076428A1 (de) 2004-09-10
SA04250153A (ar) 2005-12-03
CA2517386A1 (en) 2004-09-10
WO2004076426A1 (de) 2004-09-10
CL2004000392A1 (es) 2005-04-22

Similar Documents

Publication Publication Date Title
NO20054396D0 (no) 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
DK1756084T3 (da) Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
DK1644357T3 (da) Trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af lidelser relateret dertil
NO20055370D0 (no) Alfa-substituert karboksylsyre som PPAR modulatorer
DK1651621T3 (da) 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
DE60323060D1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
DK1678185T3 (da) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolforbindelser til behandling af tuberkulose
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1732562T3 (da) Substituerede pyridinyl- og pyrimidinylderivater som modulatorer af metabolisme og behandling af forstyrrelser relateret dertil
DZ2936A1 (fr) Composition nouvelle à libération modifiée pour letraitement du diabète.
DE60332802D1 (de) Flüssigkristallvideoprojektor
NO20044245L (no) Tiazol- og oksazolderivater som modulerer PPAR-aktivitet
DK2173730T3 (da) Hidtil ukendte forbindelser 951: biphenyloxypropansyre som crth2-modulator og mellemprodukter
NO20033683L (no) 2,4-disubstituerte pyrimidin-5-karboksamidderivater som KCNQ kaliumkanal modulatorer
DK2258688T3 (da) Pyridinon-derivater til behandling af aterosklerose
MA28563B1 (fr) 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1789403T3 (da) N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
DK1324970T3 (da) Retinoider til behandling af emfysem
NO20045554L (no) Fremgangsmate for behandling av diabetes
DK1539746T3 (da) N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes
DK1225878T3 (da) RAR-gamma-selektive retinoidagonister til behandling af emfysem
DK1551814T3 (da) Chirale oxazol-arylpropionsyrederivater og anvendelse deraf som ppar-agnister
DE60231286D1 (de) Optischer Modulator